Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01837719 · ClinicalTrials.gov registry record · Phase 1
Bioequivalence Study of Individual Atazanavir and Cobicistat Compared With Atazanavir in Fixed-dose Combination With Cobicistat
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
NCT01837719 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 64 participants.
The verdict
NCT01837719, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
Study Summary
The purpose of the study is to compare the pharmacokinetics and bioequivalence of atazanavir in a fixed-dose combination with cobicistat with that of atazanavir coadministered with cobicistat as single agents.
Interventions
- DRUG Cobicistat
- DRUG Atazanavir
- DRUG Atazanavir/Cobicistat FDC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2013-04 |
| Est. Completion | 2013-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01837719
The ClinicalTrials.gov registry entry for NCT01837719 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cobicistat is the first listed.
NCT01837719 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01837719 about?
NCT01837719 is a clinical study titled "Bioequivalence Study of Individual Atazanavir and Cobicistat Compared With Atazanavir in Fixed-dose Combination With Cobicistat". The purpose of the study is to compare the pharmacokinetics and bioequivalence of atazanavir in a fixed-dose combination with cobicistat with that of atazanavir coadministered with cobicistat as single agents.
What is the current status of trial NCT01837719?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2013-04. Estimated completion is 2013-06.
What interventions are being tested in trial NCT01837719?
The interventions under investigation include: Cobicistat (DRUG), Atazanavir (DRUG), Atazanavir/Cobicistat FDC (DRUG).
Who is sponsoring clinical trial NCT01837719?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.